// Biotech and Pharma Therapeutics
Amid measles outbreak, Texas is poised to make vaccine exemptions for kids easier
May 28, 2025 / Texas vaccine exemptions / measles outbreak 2024 / school immunization policy / childhood vaccine laws / public health vaccination debate
Despite a severe measles outbreak, Texas lawmakers passed a bill easing vaccine exemption access for schoolchildren, allowing online form downloads instead of mailed requests—potentially undermining public health efforts to prevent vaccine-preventable diseases.
GLP-1 prescriptions for weight loss soar, despite obstacles
May 28, 2025 / GLP-1 weight loss surge / obesity drug access / Wegovy Zepbound demand / GLP-1 insurance coverage / metabolic health treatment
GLP-1 prescriptions for weight loss have surged nearly sevenfold since 2019, yet over 80% of eligible U.S. adults remain untreated. Despite efficacy, high costs and limited insurance coverage continue to restrict access to these metabolic health drugs.
Pimicotinib demonstrates best-in-class potential in TGCT?
May 28, 2025 / pimicotinib TGCT trial / CSF-1R inhibitor therapy / tenosynovial giant cell tumor / TGCT Phase III results / Abbisko Merck partnership
Pimicotinib, a CSF-1R inhibitor, showed a 54% objective response rate in TGCT patients in Phase III trials, significantly outperforming placebo. It also improved key patient-reported outcomes, positioning it as a potential best-in-class therapy.
The Strategic Power of Application Rationalization in Healthcare M&A
May 28, 2025 / healthcare M&A strategy / application rationalization healthcare / IT integration in hospitals / active data archiving / healthcare digital transformation
Application rationalization in healthcare M&A reduces redundant IT systems, cuts costs, minimizes cybersecurity risks, and enhances data access. When embedded early, it accelerates integration, supports compliance, and enables innovation through modern data platforms and active archiving.
Critical Role of Transitions of Care in Medicare Advantage Success
May 28, 2025 / Medicare Advantage care transitions / post-acute care coordination / hospital discharge planning / Medicare readmission prevention / value-based senior care
Effective transitions of care are vital for Medicare Advantage success, reducing hospital readmissions, improving outcomes, and lowering costs. Health plans must coordinate medical and non-medical services, optimize post-acute care, and personalize support to improve quality ratings and retention.
// 4th Industrial Revolution
Machine-learning-assisted universal protein activation in living mice
May 27, 2025 / protein activation in vivo / bioorthogonal decaging strategy / machine learning protein engineering / therapeutic protein control / targeted T cell activation
CAGE-Proxvivo enables precise, reversible protein activation in living mice using machine learning and bioorthogonal chemistry, allowing researchers to control protein function and interactions in real time for in vivo studies and targeted therapeutic applications.
AI Draws Big Business Muscle in Healthcare
May 27, 2025 / AI healthcare innovation / generative AI in medicine / AI medical imaging diagnostics / healthcare data privacy / pharma AI drug discovery
AI in healthcare is rapidly advancing, transforming diagnostics, patient management, and drug discovery. Despite projected market growth and industry adoption, significant challenges remain around integration, regulation, bias, and workforce readiness to safely implement AI at scale.
Patients and staff share views on using AI in primary care evisits
May 27, 2025 / AI primary care / eVisit patient triage / AI healthcare communication / digital health privacy / artificial intelligence clinical workflow
Patients and primary care staff support AI-assisted eVisits if used to complement—not replace—clinicians. AI can streamline triage, prioritize urgent cases, and assist with communication, though concerns persist around depersonalization, safety, and data privacy.
FDA Outlines AI Medical Device Software Recommendations in Draft Guidance
May 23, 2025 / FDA AI device guidance / AI medical device regulation / AI bias medical software / AI lifecycle management FDA / FDA change control AI
The FDA’s 2024 draft guidance outlines lifecycle management and marketing recommendations for AI-enabled medical devices, emphasizing transparency, bias mitigation, and post-market continuous monitoring via predetermined change control plans to ensure safety and performance improvement.
WellTheory Secures $5M, Introduces New AI Tools to Support Autoimmune Care
May 26, 2025 / AI autoimmune care / WellTheory digital health / personalized autoimmune treatment / Care Scribe Care Hub / AI healthcare tools
WellTheory raised $5M to enhance AI-driven care for autoimmune diseases, launching tools that streamline care plans and data integration. Their personalized, collaborative model has shown symptom improvement across fatigue, pain, and digestion among members.
// Business & Markets
Boston Scientific Strikes Out with Yet Another TAVR Platform
May 28, 2025 / Acurate TAVR failure / Boston Scientific valve exit / TAVR clinical trial results / Acurate neo2 vs Sapien / transcatheter valve market
Boston Scientific is discontinuing its Acurate TAVR systems after poor clinical trial results and increased regulatory hurdles. This marks the company’s second TAVR exit, following Lotus, leaving Medtronic and Edwards as dominant players in the space.
Reproductive health startup raises $65M for infertility drugs
May 21, 2025 / infertility drug development / male fertility treatment / adenomyosis therapy clinical trial / IVF embryo implantation support / ReproNovo reproductive biotech
ReproNovo raised $65M to advance leflutrozole for male infertility and nolasiban for adenomyosis and IVF support. The Phase 2 trials aim to address key gaps in reproductive health with novel, mechanism-driven therapies for both men and women.
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
May 28, 2025 / cell therapy automation / decentralized CGT platform / Juno GmbH acquisition / bedside gene therapy / TQ Therapeutics CGT innovation
TQ Therapeutics has acquired Juno GmbH from Bristol Myers Squibb to accelerate development of its decentralized, automated cell and gene therapy platform, aiming to reduce production time and cost while improving access to individualized cell therapies at the point of care.
Private equity firms reportedly offer $16B-plus to acquire Hologic
May 28, 2025 / Hologic acquisition offer / private equity healthcare / TPG Blackstone bid / mammography sales decline / healthcare imaging industry
Hologic reportedly rejected a $16B+ acquisition bid from TPG and Blackstone. The imaging vendor, known for mammography systems, is facing declining sales and tariff pressures, while private equity interest underscores healthcare’s ongoing appeal to institutional investors.
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial
May 28, 2025 / ALS cell therapy / NurOwn Phase IIIb trial / BrainStorm Minaris partnership / MSC-NTF cell manufacturing / FDA orphan drug designation
BrainStorm Cell Therapeutics has partnered with Minaris Advanced Therapies to manufacture NurOwn for its FDA-cleared Phase IIIb ALS trial. NurOwn uses autologous MSC-NTF cells and holds orphan drug designation for treating neurodegenerative diseases, including ALS.
// Legal & Regulatory
Abbott wins FDA approval for mitral valve replacement device, teeing up Edwards competition
May 28, 2025 / Tendyne valve FDA approval / Abbott mitral valve device / mitral annular calcification treatment / transcatheter valve replacement / Edwards Abbott valve competition
Abbott’s Tendyne transcatheter mitral valve replacement system received FDA approval for treating severe mitral annular calcification in patients unsuitable for surgery, offering a minimally invasive solution and expanding competition with Edwards in the mitral valve market.
US FDA approves use of Sanofi’s meningococcal vaccine in infants
May 27, 2025 / meningococcal vaccine infants / MenQuadfi FDA approval / Sanofi infant vaccine / meningitis vaccine under 1 / Neisseria meningitidis prevention
The FDA approved Sanofi’s MenQuadfi for use in infants as young as six weeks, making it the first meningococcal vaccine available for that age group to protect against four common bacterial strains causing severe and potentially deadly infections.
With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon
May 28, 2025 / Alzheimer’s vaccine development / amyloid tau vaccine / Nuravax Duvax Alzheimer’s / FDA Alzheimer’s blood test / Alzheimer’s early detection therapy
Following FDA clearance of the first Alzheimer’s blood test detecting amyloid plaques, biotech firms like Nuravax are advancing vaccine candidates to target amyloid and tau proteins early—potentially preventing cognitive decline before symptoms appear.
FDA fast-tracks Teva’s coeliac disease treatment
May 28, 2025 / Teva coeliac treatment / IL-15 antibody therapy / FDA fast track coeliac / TEV-53408 clinical trial / gluten-free diet limitations
The FDA has granted fast-track status to Teva’s TEV-53408, an anti-IL-15 antibody in Phase 2a trials for coeliac disease. The therapy targets inflammation beyond diet alone, aiming to reduce intestinal damage and improve outcomes for patients on gluten-free diets.
FDA refuses to file Savara BLA for Molbreevi
May 28, 2025 / Molbreevi FDA refusal / Savara pulmonary alveolar proteinosis / BLA CMC deficiencies / molgramostim regulatory update / autoimmune PAP treatment
The FDA issued a Refuse to File letter for Savara’s BLA submission of Molbreevi (molgramostim) for autoimmune pulmonary alveolar proteinosis, citing incomplete CMC data. No safety or efficacy concerns were raised; Savara plans a Type A meeting.
// Research & Development
Muscle-sparing obesity drug safe for Phase 3 trial, Veru says
May 28, 2025 / enobosarm obesity treatment / muscle-sparing weight loss / Wegovy combination therapy / obesity drug Phase 3 / GLP-1 muscle preservation
Veru’s enobosarm, combined with Wegovy, preserved lean muscle mass in older adults with obesity without adding significant side effects, supporting its advancement to Phase 3 trials. The combo may address a key limitation of GLP-1 therapies: muscle loss.
GSK-licensed antibiotic meets goal in late-stage study
May 28, 2025 / GSK tebipenem HBr / oral carbapenem antibiotic / complicated urinary tract infection / antibiotic resistance treatment / Phase 3 UTI trial
GSK’s oral carbapenem antibiotic, tebipenem HBr, met efficacy and safety goals in a Phase 3 trial for complicated urinary tract infections, potentially becoming the first oral treatment of its kind and aiding efforts against antimicrobial resistance.
Personalized molecular signatures of insulin resistance and type 2 diabetes
May 27, 2025 / insulin resistance biomarkers / type 2 diabetes heterogeneity / skeletal muscle proteomics / personalized diabetes treatment / phosphoproteome analysis
Using advanced proteomics, researchers identified molecular signatures in skeletal muscle that predict insulin sensitivity and reveal preserved insulin signaling despite resistance. These personalized profiles highlight the importance of accounting for disease heterogeneity in precision type 2 diabetes care.
InflaRx ditches vilobelimab Phase III trial in PG
May 28, 2025 / vilobelimab trial halted / pyoderma gangrenosum treatment / InflaRx Phase III failure / C5aR inhibitor INF904 / chronic immune dermatology drug
InflaRx has terminated its Phase III trial of vilobelimab for pyoderma gangrenosum after an interim analysis showed futility. No unexpected safety issues were reported. The company will shift focus to its oral C5aR inhibitor, INF904.
Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono
May 28, 2025 / pimicotinib TGCT treatment / Merck KGaA phase 3 data / CSF-1R inhibitor efficacy / noncancerous tumor therapy / Turalio vs pimicotinib
Merck KGaA’s CSF-1R inhibitor, pimicotinib, showed strong Phase 3 efficacy for tenosynovial giant cell tumor (TGCT), achieving significant tumor reduction, functional improvement, and no major liver toxicity—positioning it as a safer competitor to Daiichi’s Turalio ahead of regulatory filings.
// Politics
Big Pharma likely to endure Trump’s tariff, pricing pressures, but threats to generics persist: S&P
May 28, 2025 / drug pricing reform / pharmaceutical tariffs / generic drugmakers risk / Big Pharma resilience
S&P Global reports that while Big Pharma may weather Trump-era tariff and pricing pressures, smaller generic manufacturers face serious risks. Policies like Most Favored Nation pricing and pharmaceutical tariffs could reshape industry economics and strain U.S. generic drug supply chains.
CDC pulls COVID vaccine recommendation for pregnant women, healthy children: RFK Jr.
May 27, 2025 / COVID vaccine policy / CDC recommendations change / pregnant women COVID vaccine / healthy children vaccination / FDA booster guidance
The CDC has removed COVID-19 vaccines from its routine recommendations for pregnant women and healthy children, citing insufficient clinical data. New FDA policy emphasizes robust trials before approving vaccines for low-risk groups, impacting future vaccine updates and access.
RFK Jr. threatens to bar government scientists from publishing in leading medical journals
May 27, 2025 / RFK Jr. medical journals / NIH publishing policy / pharma influence research / scientific journal integrity / Kennedy NIH controversy
HHS Secretary Robert F. Kennedy Jr. threatened to ban NIH scientists from publishing in top medical journals, citing pharmaceutical industry bias. He proposes in-house alternatives, clashing with NIH leadership who support academic freedom and publication in established scientific outlets.
Simon Harris warns US of tariff impact on pharma and microchip sectors
May 25, 2025 / pharmaceutical tariffs US / Ireland pharma exports / Simon Harris trade warning / US drug import policy / pharma supply chain resilience
Simon Harris warned the U.S. that imposing tariffs on pharmaceutical imports could harm bilateral trade and supply chain resilience. He emphasized Ireland’s critical role in U.S. pharma manufacturing, particularly in active ingredient production, and urged economic cooperation over protectionism.
Oklahoma Joins Push Against Big Pharma Ads with Sweeping Bill.
May 27, 2025 / Oklahoma pharma ad ban / SB771 drug marketing law / opioid crisis advertising / direct-to-consumer drug ads / pharmaceutical regulation USA
Oklahoma’s SB771 aims to ban direct-to-consumer pharmaceutical advertising across media platforms, citing public health concerns and past crises like the opioid epidemic. The bill seeks to protect medical decision-making from marketing influence and restore clinician-patient trust.